{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-093153","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2023-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.058938+00:00","generated_at":"2026-06-17T05:13:37.467205+00:00","sec_items":["1.01","1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Magenta Therapeutics pays $14.8M to terminate Cambridge sublease with Novartis","bullets":["One-time termination payment of $14,780,188 to Novartis for early exit from 69,000 sq ft sublease.","Sublease originally scheduled to end Feb 2028 or earlier; terminated effective March 31, 2023.","Principal executive offices moving to 300 Technology Square, Cambridge, MA.","Sublease covered R&D, laboratory, and office space at 100 Technology Square."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-093153","json":"https://secwatch.observer/filing/0001193125-23-093153.json","markdown":"https://secwatch.observer/filing/0001193125-23-093153.md","text":"https://secwatch.observer/filing/0001193125-23-093153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523093153/0001193125-23-093153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523093153/d488935d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:13:37.467205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}